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CLINICAL INVESTIGATION

Chronic Use of Angiotensin Converting Enzyme
Inhibitors and/or Angiotensin Receptor Blockers is
Not Associated With Stroke After Noncardiac Surgery:
A Retrospective Cohort Analysis
Shobana Rajan, MD,*† Sanchit Ahuja, MD,*‡ Barak Cohen, MD, MHA,*§
Adriana Martin, MD,∥ Amanda Pursell, MD,∥ Chen Liang, MS,*¶ Guangmei Mao, MPH, PhD,*¶
Ryu Komatsu, MD,# Ehab Farag, MD,*∥ and Daniel I. Sessler, MD*

Background: Inhibition of the renin-angiotensin-aldosterone
pathways reduces blood pressure and proliferation of vascular
smooth muscles and may therefore reduce the risk of stroke. We
tested the hypothesis that patients taking angiotensin converting
enzyme inhibitors (ACEIs) or angiotensin receptor blockers
(ARBs) for at least 6 months have fewer postoperative strokes
after non-neurological, noncarotid, and noncardiac surgeries
than those who do not.
Methods: We considered adults who had noncardiac surgery at
the Cleveland Clinic between January 2005 and December 2017.
After excluding neurological and carotid surgeries, we assessed
the confounder-adjusted association between chronic use of
ACEIs/ARBs (during 6 preoperative months) and the incidence
of postoperative stroke using logistic regression models.
Results: Postoperative strokes occurred in 0.26% (27/10,449) of
patients who were chronic ACEI/ARBs users and in 0.18% (112/
62,771) of those who were not. There was no signiﬁcant association between ACEI/ARB use and postoperative stroke, with an
adjusted odds ratio of 1.15 (95% conﬁdence interval [CI]:
0.91-1.44; P = 0.24). Secondarily, there was no association
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between exposures to ACEIs and postoperative stroke, versus no
such exposure (adjusted odds ratio 0.88, 95% CI: 0.65-1.19;
P = 0.33). Similarly, there was no association between exposure
to ARBs and postoperative stroke, versus no such exposure
(adjusted odds ratio 1.05, 95% CI: 0.75-1.48; P = 0.75).
Conclusion: We did not detect an effect of chronic ACEI/ARB
use on postoperative strokes in patients who had non-neurological, noncarotid and noncardiac surgery; however, power was
extremely limited.
Key Words: anesthesia, angiotensin receptor antagonists, angiotensin receptor blocker, postoperative cognitive complications,
ischemic stroke, postoperative complications
(J Neurosurg Anesthesiol 2022;34:401–406)

P

ostoperative strokes are rare. For example, the incidence of clinically apparent perioperative stroke is
reportedly around 0.7% after hemicolectomy, 0.2% after
hip replacement, and 0.6% after lobectomy or segmental
lung resection.1 Unsurprisingly, the incidence is greater in
older patients and up to 90% of perioperative strokes occur in patients with a previous stroke history.1,2 Perioperative strokes are devastating; roughly a third of the
patients die within 1 month and another third are permanently incapacitated.3 Mortality from perioperative
stroke exceeds that from nonoperative stroke.4
Endothelial dysfunction may contribute to perioperative stroke. The neuroendocrine response to surgery
provokes a cascade of inﬂammatory mediators and cytokines that triggers inﬂammatory responses in vessels,
which makes them vulnerable to thrombosis.5,6 Hyperactivity of the renin-angiotensin-aldosterone system is
thought to contribute to the pathogenesis of stroke via its
vasoconstrictor effects on cerebral vasculature and oxidative effects on brain parenchyma.7,8 Inhibition of the
renin-angiotensin-aldosterone pathways blunts the neuroendocrine response to surgery and enhances ﬁbrinolysis,
stabilizes plaque, decreases the risk of plaque rupture, and
Renin-angiotensin-aldosterone
reduces
thrombosis.9
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inhibition also reduces the proliferation of vascular
smooth muscle, improves vascular compliance and reduces the cerebral vasoconstriction consequent to angiotensin II, thus potentially reducing stroke risk via 2
mechanisms.10 For example, inhibition of reninangiotensin-aldosterone for at least 6 to 9 months measurably decreases carotid intimal medial thickness,11–15
thereby potentially reducing stroke risk.16,17 The most
commonly used renin-angiotensin-aldosterone inhibitors
are angiotensin converting enzyme inhibitors (ACEIs) and
angiotensin receptor blockers (ARBs).
Previous work performed in nonsurgical settings suggests a beneﬁt of chronic effects of renin-angiotensin-aldosterone pathway inhibition on stroke reduction, and that
the beneﬁt may be independent of blood pressure
reduction.7,18–22 However, meta-analyses also suggest that
chronic use of ACEIs or ARBs may have different effects on
strokes.22–24 It thus remains uncertain whether the chronic
use of ACEIs/ARBs has a plausible role in postoperative
stroke reduction. We therefore tested the hypothesis that
patients who take ACEIs or ARBs during the 6 months
before non-neurological, noncarotid, noncardiac surgeries
have fewer postoperative strokes than those who do not.

METHODS
With approval from the Cleveland Clinic Institutional
Review Board (IRB 17-035, March 1, 2017) and waived
patient consent, we extracted patient information from
electronic medical records and perioperative health documentation systems. In this retrospective, single-center,
cohort study, we considered adults with American Society
of Anesthesiologists (ASA) Physical Status I to IV who had
non-neurological, noncardiac, and noncarotid surgeries at
the Cleveland Clinic Main Campus between January 2005
and December 2017. For patients who had multiple surgeries during this period, we included only the index surgery
for each patient’s last surgical hospitalization. Patients were
excluded if key demographic or baseline characteristics or
perioperative variables were missing.
The exposure was chronic use of ACEIs/ARBs for at
least 6 months before the index surgery, irrespective of
whether the drug was withheld on the day of surgery.
A 6-month window was chosen for ACEI/ARB exposure
because that is the minimum time required to ameliorate
carotid intimal thickening.15,25 Chronic use of ACEIs or
ARBs was retrieved from the electronic medical records
system by searching Cleveland Clinic pharmacy records.
Reference patients were those who did not have active
ACEI/ARB pharmacy orders for at least 6 months before
surgery. For subgroups of ACEI/ARB-treated patients,
the “ACEI only group” consisted of patients who did not
have an active pharmacy order for ARBs for at least
6 months, and the “ARB only group” consisted of patients
who did not have an active pharmacy order for ACEIs for
at least 6 months. We excluded patients in whom drug
prescriptions were interrupted > 90 days in the preoperative 6 months.26,27
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Postoperative stroke was our primary outcome. We
deﬁned postoperative stroke as ischemic, embolic, hemorrhagic, or thrombotic cerebrovascular events that occurred during or within 30 days after surgery and were
documented radiologically. We ﬁrst identiﬁed potential
postoperative stroke cases using the International Classiﬁcation of Diseases, Ninth Revision, codes. Potential
strokes were independently assessed by 2 investigators
(A.M. and A.P.), and discrepancies were adjudicated by
2 other investigators (S.R. and S.A.).
Types of surgery were characterized using the
Agency for Healthcare Research and Quality’s Clinical
Classiﬁcations Software for Services and Procedures. Both
the exposure and the outcome were deﬁned a priori. This
manuscript adheres to the guidelines of Strengthening the
Reporting of Observational Studies in Epidemiology.

Statistical Analysis
Confounder Adjustment
Patient demographic and baseline comorbidities
were considered as potential confounding variables in this
study. As proxy for surgery risk and complexity, surgery
type and surgery duration were controlled through inverse
probability of treatment weighting. On the basis of inverse
of probability of receiving treatment, weights were assigned to the included patients to form a pseudopopulation where the treatment and control groups were
balanced on the confounding variables. For example,
smaller weights were assigned to patients with a higher
probability of receiving treatment whereas larger weights
were assigned to patients with a lower probability of receiving treatment. Weighting was estimated as the inverse
of the propensity score for patients who received the
treatment, and as the inverse (1−propensity score) for the
control patients. To avoid extremes, weights smaller than
the ﬁrst percentile were rounded up to the value of ﬁrst
percentile and weights greater than the 99th percentile
were rounded down to the value of the 99th percentile.
The propensity score was then calculated as the probability of receiving the treatment, estimated from a multivariable logistic regression model that incorporated all the
variables shown in Supplemental Digital Content 1
(Supplementary Table 1: Summary patient proﬁle before
and after inverse probability of treatment weighting by
ACEI/ARB use, http://links.lww.com/JNA/A377) as predictors, independent of the treatment assignment. Because
we included patients over a wide timeframe, we also included year of surgery as a categorical variable in the
propensity score model to control for the time effect from
changing techniques more thoroughly.
For each treatment, we assessed the balance on patients’ demographics and baseline comorbidities after
weighting, using absolute standardized difference. Variables with absolute standardized difference > 0.20 were
considered as imbalanced between treatment and control
groups, and such variables, except for type of surgery,
were adjusted for directly in the analysis model after
weighing the patients.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
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Analysis
For the primary analysis, we assessed the confounderadjusted association between preoperative use of ACEIs/
ARBs and postoperative stroke using logistic regression
models, adjusting for confounding variables as described
earlier. Odds ratios with 95% conﬁdence intervals (CI) are
reported. For the secondary analysis, we assessed the association between preoperative use of ACEIs and postoperative stroke and between preoperative use of ARBs
and postoperative stroke separately, each using a logistic
regression model with adjustment for potential confounders
as described earlier. The 2 exposures were compared in
separate models to allow for better adjustment of potential
confounding variables. Signiﬁcance criteria of 0.05/
2 = 0.025 were applied under the Bonferroni correction,
adjusting for testing 2 exposures simultaneously.

Post Hoc Power Estimation
Because of the overall low incidence of postoperative
strokes (< 0.1%), we included all available patients who
had surgery between January 2005 and December 2017.
With 10,449 ACEI/ARB users and 62,771 controls, we
had 17% power to test an odds ratio of 0.8 and 80% power
for an odds ratio of 0.45 or smaller, under the incidence of
0.19% for postoperative stroke.

RESULTS
We identiﬁed 173,351 surgeries in 164,204 patients
who met our inclusion/exclusion criteria and considered
164,204 index surgeries from the patients’ last surgical
hospitalization in the analysis (Fig. 1). A total of 4569
(2.8%) patients were excluded under a complete case
analysis, assuming that all missingness was at random
after inspection of the missing patterns. 23,170 patients
who used ACEIs or ARBs within 1 year but did not satisfy
chronic ACEI/ARB use were excluded from the control
group. An additional 63,245 surgeries were excluded while
matching patients according to surgery types with no
postoperative stroke. Postoperative stroke was identiﬁed
in 46 surgery types, involving 139 strokes cases from
73,220 patients, with an incidence rate of 0.19%. Stroke
types included 8 (6%) cases of occlusion and stenosis of
precerebral arteries, 23 (16%) cases of hemorrhagic stroke
and 108 (78%) cases of occlusion of cerebral arteries
(Supplemental Digital Content 2, Supplementary Table 2:
Type of postoperative strokes, http://links.lww.com/JNA/
A378).
For the primary analysis, 10,449 (14.3%) patients
used ACEIs/ARBs for at least 6 months before the index
surgery, of whom 500 (0.7%) used both ACEIs and ARBs,
6848 (9.4%) used ACEIs only and 3101 (4.2%) used ARBs
only. The incidence of postoperative stroke was 0.26% (27/
10,449) in ACEI/ARB users and 0.18% (112/62,771) in the
control group (Table 1).
Demographics and baseline comorbidities summarized by ACEI/ARB use are shown in Supplemental Digital
Content 1 (left panel of Supplementary Table 1, http://
links.lww.com/JNA/A377). Patients who used ACEIs/

Chronic ACEI/ARBs and Postoperative Stroke

ARBs were older, had higher body mass index, worse
ASA physical status, and were more likely to have congestive heart failure, peripheral vascular disease, hypertension, diabetes, renal failure, and coronary artery
disease compared with controls. The 2 groups were also
unbalanced on race or surgery type. After inverse probability of treatment weighting, control and treatment
groups were still not balanced for age, ASA physical status, hypotension, diabetes, renal failure, coronary artery
disease or surgery type (Supplementary Digital Content 1:
Right panel of Supplementary Table 1, http://links.lww.
com/JNA/A377). After confounder adjustment, there was
no signiﬁcant difference between ACEI/ARB users and
the control group, with an odds ratio of 1.15 (95% CI:
0.91-1.44; P = 0.24), comparing ACEI/ARB users to controls (Table 1).
For subgroups in the treatment group, the incidence
of postoperative stroke was 0.24% (17/6848) for patients
who used ACEIs only and 0.23% (7/3101) for patients who
used ARBs only. Compared with the control group, patients who used ACEIs only or who used ARBs only did
not have lower incidence of stroke after confounder adjustment, with odds ratios of 0.88 (97.5% CI: 0.65-1.19;
P = 0.33) and 1.05 (97.5% CI: 0.75-1.48; P = 0.75), respectively (Table 1). Patient proﬁles for “ACEI only
users” and for “ARB only users” are summarized in
Supplemental Digital Contents 3 and 4, respectively
(Supplementary Table 3: Patient proﬁles before and after
inverse probability of treatment weighting by ACEI use,
http://links.lww.com/JNA/A379, Supplementary Table 4:
Summary of patient proﬁle before and after inverse
probability of treatment weighting by ARB use, http://
links.lww.com/JNA/A380).

DISCUSSION

In contrast to our expectations, we did not ﬁnd a
statistically signiﬁcant or clinically meaningful association
between chronic ACEI or ARB exposure and postoperative stroke. With a total of 139 strokes, we had 17%
power to detect a 20% reduction in an event. Thus, while
our power was low, there was also no evidence that ACEI/
ARB treatment reduces stroke risk. Even if beneﬁt is
identiﬁed at some point, the number needed-to-treat
would certainly be prohibitive. We speciﬁcally evaluated
the effects of chronic inhibition (at least 6 mo) of reninangiotensin-aldosterone on postoperative stroke, irrespective of whether a preoperative dose was withheld on
the day of surgery. Importantly, the neuroprotective effects of ACEIs and ARBs on carotid intimal medial
thickness appear to depend on duration of exposure.14,18–21,28,29 Our results are consistent with a systematic review that reported no meaningful associations between preoperative ACEI/ARB use and perioperative
complications such as stroke, myocardial infarction and
unplanned intensive care unit admission.30 However, a
meta-analysis reported fewer cerebrovascular events
among 459 cardiac surgery patients who continued
ACEIs/ARBs (relative risk 0.48, 95% CI: 0.18-1.28;
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FIGURE 1. Study flow chart. ACEIs indicates angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers.

TABLE 1. Incidence of Postoperative Stroke in ACEI/ARB Users
and Controls
Incidence of Postoperative
Stroke
Treatment
Primary
ACEI/ARB
Secondary
ACEI
ARB

Treatment

Control

Odds Ratio (CI)

P

0.26%
(27/10,449)

0.18%
(112/62,771)

1.15
(95% CI: 0.91-1.44)

0.24

0.24%
(17/6848)
0.23%
(7/3101)

0.18%
0.88
0.33
(112/62,771) (97.5% CI: 0.65-1.19)
0.18%
1.05
0.75
(112/62,771) (97.5% CI: 0.75-1.48)

ACEI indicates angiotensin converting enzyme inhibitors; ARB, angiotensin
receptor blockers; CI, conﬁdence interval.
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P = 0.14).31 Importantly, this outcome was a secondary
analysis and there were only 17 strokes, making the results
fragile. The clinical beneﬁt and reproducibility of neuroprotective effects of ACEIs/ARBs were also found to
differ when compared with other antihypertensives in
nonsurgical settings. In a recent Cochrane review of 4
trials, for example, the authors report an increased incidence of stroke in patients who took renin-angiotensinaldosterone inhibitors (relative risk 1.19, 95% CI: 1.081.32; absolute risk increase 0.7%) when compared with
thiazides and calcium channel blockers, but a decreased
incidence of stroke when compared with beta blocker use
(relative risk 0.75, 95% CI: 0.63-0.88; absolute risk reduction 1.7%).32 An important limitation in this review
was the unbalanced proportion of other antihypertensive
drugs and the uncertainty that the study drugs were balanced between treatment groups.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
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There are 2 major mechanisms by which ACEIs and
ARBs might reduce stroke risk. The ﬁrst is the vascularprotective effect on proliferation of endothelial smooth
muscle. Inhibition of the renin-angiotensin-aldosterone
system reduces vascular smooth muscle proliferation and
prevents plaque destabilization. This property of ACEIs/
ARBs has been evaluated in clinical trials and a metaanalysis in nonsurgical settings.33 Four major trials showed
a beneﬁt of renin-angiotensin-aldosterone pathways inhibition on stroke, and that the beneﬁt appears to be distinct from blood pressure reduction, possibly involving
neurohormonal effects such as remodeling.18–21,28,29 Additional data demonstrate that renin-angiotensin-aldosterone
blockade and statin therapy improve endothelial cell function and suppress oxidative stress.34 The second mechanism
is reduction of angiotensin II related vasoconstrictor effects
on cerebral vessels via down-regulation of angiotensin receptors (angiotensin type 1 receptors) within brain
parenchyma.7,35 Circulating angiotensin II has contractile
effects on cerebral arteries, which may worsen cerebral
perfusion and lead to ischemia.8 Furthermore, animal data
suggest that angiotensin II increases oxidative stress.35
Notably, the effects of these mechanisms are independent of
blood pressure control.
Many anesthesia practitioners withhold ACEIs and
ARBs on the day of surgery in an effort to avoid intraoperative hypotension. A recent meta-analysis conﬁrmed
that withholding ACEIs/ARBs is associated with less
frequent intraoperative hypotension.36 In addition, in that
analysis the incidence of cerebrovascular events did not
differ signiﬁcantly in those who continued or withheld
ACEIs/ARBs on the day of surgery (odds ratio 0.95, 95%
CI: 0.44-2.06), however, the CI was wide indicating inconclusive evidence of any beneﬁt or harm.36 A few
studies directly investigated the association of intraoperative hypotension and postoperative strokes. No association was found between mild intraoperative
hypotension and stroke in general surgical patients.37 In a
systemic review of 4 studies, nonsigniﬁcant, small associations were noted between intraoperative hypotension and
ischemic strokes.38 In contrast, an increased risk of ischemic strokes were found with increased severity and
duration of intraoperative hypotension.39,40 Notably, the
strength of associations and effect estimates were signiﬁcantly different among these studies with respect to the
chosen intraoperative hypotension model, perhaps due to
limited statistical power. Nevertheless, the neuroprotective
effects of ACEIs and ARBs observed in nonsurgical settings are presumably due to neurohormonal involvement,
such as remodeling.19–21,29
A limitation of our analysis is that ACEIs and ARBs
were presumably prescribed primarily to treat hypertension. It therefore remains possible that doses and exposure duration were insufﬁcient for vascular-protective
effects. We relied on electronic medical pharmacy records
to identify chronic ACEI/ARB exposure and excluded
23,170 patients who had preoperative drug interruptions.
We were also unable to account for various types of
ACEIs and ARBs in our analysis. We selected a

Chronic ACEI/ARBs and Postoperative Stroke

pre-exposure cutoff of 6 months based on sonographic
ﬁnding of carotid intimal medial thickness reduction,15,25
but it is possible that intimal thinning correlates poorly
with clinical outcomes. The imbalances in our treatment
and control groups on variables (such as age, ASA status
and surgery types) persisted even after propensity score
weighting. Although we adjusted for most of the possible
confounding variables, unmeasured confounding cannot
be excluded. We intentionally restricted our analysis to
clinically apparent strokes, which is clinically meaningful.
Less severe complications, such as transient ischemic attacks, covert strokes, postoperative cognitive dysfunction,
seizures, and transient paralysis, were not included in our
analysis. Lastly, registry studies evaluating rare events,
such as perioperative strokes, are challenging due to their
extremely low incidence and sometimes poor coding in
electronic health records.
In summary, our analysis does not support the hypothesis that chronic use of ACEIs and ARBs reduces
postoperative stroke in patients having non-neurological,
noncardiac, and noncarotid surgery. There is considerable
evidence that ACEIs and ARBs are effective antihypertensive
agents and independently reduce serious cardiovascular
complications and overall mortality. But, within the limits of
low power, preventing perioperative strokes does not appear
to be among their beneﬁts.
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